TP53 and familial pancreatic carcinoma: The strongest gemcitabine-resistant pancreatic cancer cells we tested in this study preferentially enter a senescent-like phenotype, instead of dying, in response to gemcitabine, and this response is also independent of p53 as p53 is mutated in Panc1 cells [32].